Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
55 results about "PARKINSON'S SYNDROME" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural instability. It is found in Parkinson's disease (PD)—after which it is named—dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD), and many other conditions.
Use of fumaric acid derivatives for treating mitochondrial diseases
The present invention relates to the use of individual fumaric acid derivatives or mixtures thereof for preparing a pharmaceutical composition for treating mitochondrial diseases, especially for treating Parkinson's syndrome, Alzheimer's disease, Chorea Huntington disease, retinopathia pigmentosa and mitochondrial encephalomyopathy. Preferably, the fumaric acid derivative(s) is / are those selected from the group consisting of fumaric acid dialkyl esters or fumaric acid monoalkyl esters in the form of the free acid or a salt thereof.
Owner:BIOGEN INT
Derivate von dihydroxyphenylalanin
The invention relates to dihydroxyphenylalanine derivatives, the production thereof, and pharmaceutical compositions containing said dihydroxyphenylalanine derivatives. The invention further relates to the use of said dihydroxyphenylalanine derivatives and pharmaceutical compositions for the treatment and prevention of movement disorders, neurodegenerative diseases, Alzheimer, Parkinson's disease, hemiatrophy hemiparkinsonism, Parkinson's syndrome, Lewy bodies disease, frontotemporal dementia, Lytico-Bodig disease (Parkinsonism-dementia-amyotrophic lateral sclerosis, striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive pallidal atrophy, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X chromosome-linked dystonia (Morbus Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless leg syndrome, Wilson's disease.
Owner:ELLNEUROXX LTD
Medicine for treating parkinson's disease and Parkinson's syndrome and its prepn
The medicine for treating Parkinson's disease and Parkinson's syndrome is prepared with ten kinds of Chinese medicinal materials including white peony root, hooked uncaria, gastrodia tuber, puncture vine, abalone shell, etc. It is prepared through the process including the following steps: A. refluxing hooked uncaria, gastrodia tuber, prepared fleeceflower root and red sage with alcohol solution of 10-90 % concentration for several times, merging the extracted liquid and filtering; B. concentrating the filtrate to relative density of 1.0-1.3 while recovering alcohol; C. twice decocting the other medicine materials together with the refluxed dregs, filtering, merging filtrate and alcohol extracted liquid, and concentration to relative density of 1.1-1.4; and D. adding proper amount of supplementary material to prepare medicine preparation. The present invention has unique process and obvious curative effect.
Owner:GUANGDONG ZHONGSHENG PHARMA
Epas1 Gene Transfer to Improve Cell Therapy
InactiveUS20070286848A1Promote cell survivalConducive to survivalBiocidePeptide/protein ingredientsMammalNeuro-degenerative disease
The present invention concerns the use of nucleotide sequences encoding EPAS1, HIF-1α and HIF-3α transcription factors and functional analogs for treating coronary and cardiac diseases in mammals. The use of such transcription factors and its analogs is useful in the treatment of disorders that may be treated by cell therapy such as peripheral vascular disease (PVD), neurodegenerative disease including Parkinson's syndrome, muscular dystrophies, stroke, diabetes, hemophilia, wound and others.
Owner:PERFUSION THERAPEUTICS
Active metabolic product of phencynonate and its medicinal use
The present invention relates to the active metabolic product of phencynonate, N-nor phencynonate, or its pharmaceutically acceptable salt, its preparation process and the medicinal use in preparing medicine for car sickness, sea sickness and other motion sickness, Meniere's syndrome and other kinds one dizziness. The said active metabolic product and its pharmaceutically acceptable salt may be also used in treating or remitting Parkinson's disease or Parkinson's syndrome with less side effect than phencynonate.
Owner:BEIJING ZHONGYUANHENGKANG BIOTECHNOLOGY CO LTD
Application of dihydromyricetin to prepare medicines treating Parkinson's syndrome as active composition
InactiveCN104116730ALow toxicityNo toxicityOrganic active ingredientsNervous disorderBlood drug concentrationEstrogens catechol
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Synergistic combinations of norketamine and opioid analgesics
InactiveUS20080132531A1Rapid introductionExcellent dose-to-effect administration of drugBiocideNervous disorderHeadachesAnalgesic agents
The present invention relates to methods of alleviating pain with the administration of norketamine with a narcotic. More particularly, the invention provides a method of alleviating pain through the administration of a dose of norketamine, which, if administered alone would provide sub-optimal analgesic relief, yet provides analgesic relief when combined with a narcotic. In some embodiments, the combination of norketamine with a narcotic, further allows for the administration of a dose narcotic, which would be sub-optimal if used alone, but provides adequate pain relief in combination with norketamine. The invention relates to self-management of pain on an outpatient basis comprising administering via conventional routes, including transdermal, nasal, rectal, oral, transmucosal, intravenous, intramuscular, and other routes, one or more doses of norketamine / opioid compositions effective to alleviate pain to a subject suffering from pain. Uses of norketamine / opioid compositions would also apply, to treating headaches, drug abuse, mood and anxiety disorders, as well as other, neuropsychiatric disorders, both motoric and cognitive, such as Alzheimer's disease, Parkinson's syndrome, which are thought to be caused by neurodegeneration.
Owner:UNIV OF KENTUCKY RES FOUND
Phencynonate hydrochloride double-layer osmotic pump controlled release tablet and preparation method thereof
ActiveCN103284974AAvoid large fluctuations in blood concentrationImprove effectivenessOrganic active ingredientsSenses disorderMotion sicknessSide effect
The invention provides a phencynonate hydrochloride double-layer osmotic pump controlled release tablet and a preparation method thereof. The tablet comprises, from interior to exterior, a double-layer tablet core prepared through compaction of a drug-containing layer and a boosting layer, a semipermeable coating film with drug releasing holes and a moistureproof coating film, wherein the drug-containing layer contains an effective amount of phencynonate hydrochloride, a suspending aid, an osmotic pressure promoter and other pharmaceutic adjuvants, the boosting layer contains a propellant, an osmotic pressure promoter, a sustained releasing agent and other pharmaceutic adjuvants, and the semipermeable coating film is perforated with more than one drug releasing hole in one side close to the drug-containing layer. According to the invention, the phencynonate hydrochloride double-layer osmotic pump controlled release tablet has a substantial zero order drug release characteristic and enables drugs to enter into a human body at a constant speed; drug release behavior is not affected by gastrointestinal peristalses, pH values, food effects and the like, individual difference of the drug release behavior is small, and blood concentration is steady; the tablet has long-lasting drug effects, is taken once per day, has little toxic and side effects and good compliance in administration and can be used for preventing or treating motion sickness syndrome, Parkinson' disease, Parkinson' disease syndrome, acute attack of vertigo and epilepsy.
Owner:WUHAN GENERAL HOSPITAL OF GUANGZHOU MILITARY
Parkinson's syndrome aided prediction method based on multi-label model
InactiveCN104794339AImprove accuracySpecial data processing applicationsMulti-label classificationPredictive methods
The invention relates to a Parkinson's syndrome aided prediction method based on a multi-label model. Prediction model building, balance evaluation and mining prediction stage processing modules are included. In the prediction model building module, a main syndrome is selected; K secondary syndromes are selected; the main syndrome and the K secondary syndromes form a new syndrome set; the balance of the syndrome set is evaluated; if the balance meets the conditions, the relevance between the main syndrome and the secondary syndromes is determined, and otherwise, the second step is carried out again; the syndrome set serves as training data to build the multi-label model. In the balance evaluation module, obtained syndrome sets are combined; the number and occurrence frequency of the syndrome combinations are counted; according to an information entropy formula, the entropy of the syndrome sets is calculated; the process is ended. In the prediction stage, the given to-be-predicted data are transmitted to the model to be classified; all the classification results of the model are voted, and a final prediction result is obtained. The method solves the problem that a multi-label classification algorithm is not accurate in prediction under sparse category and unbalanced conditions.
Owner:NANJING UNIV
Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient
Owner:ONO PHARMA CO LTD
Selectivity M4 acceptor antagonist and medical use thereof
ActiveCN101209994AOrganic active ingredientsNervous disorderPharmaceutical drugBULK ACTIVE INGREDIENT
Owner:BEIJING ZHONGYUANHENGKANG BIOTECHNOLOGY CO LTD
Traditional Chinese medicine composition for treating Parkinson's syndrome and preparation method thereof
InactiveCN109692279ABalance yin and yangQi and blood accessibleNervous disorderAnthropod material medical ingredientsSalvia miltiorrhizaHuman body
The embodiment of the invention discloses a traditional Chinese medicine composition for treating Parkinson's syndrome and a preparation method thereof, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30-50 parts of calculus bovis, 50-80 parts of stir-fried cape jasmine, 50-80 parts of cortex phellodendri processed with wine, 45-55 parts of radix scutellariae, 40-55 parts of rhizoma picrorhizae, 100-150 parts of prepared whole worms, 50-80 parts of ligusticum chuanxiong prepared with semen lepidii, 50-80 parts of radix salviae miltiorrhizae prepared with semen lepidii, 100-120 parts of rhizoma gastrodiae, 100-120 parts of salt-fried eucommia ulmoides, 30-50 parts of radix achyranthis bidentatae, 100-150 parts of calcined oysters, 50-80 parts of leeches processed with wine, 50-80 parts of centipedes processed with wine, 40-60 parts of uncaria rhynchophylla, 100-150 parts of white paeony root stir-fried with bran, and 50-80 parts of prepared bombyx batryticatus. The traditional Chinese medicine composition for treating Parkinson's syndrome is capable of harmonizing qi and blood, nourishing Yang and tonifying kidney, dredging collaterals and relieving pain, dredging and nourishing governor and conception vessels, nourishing brain and improving intelligence, balancing Yin and Yang of human body, and making qi and blood dredged, has the advantages of obvious curative effect, high safety and no toxic or side effects, and is suitable for long-term taking.
Owner:孙国榆
Drug for treating symptoms of later stage of chronic manganese poisoning
InactiveCN105641570ARelief of Parkinson's SyndromeRemissionDispersion deliveryAntinoxious agentsSyneilesisTree root
The invention discloses a drug for treating symptoms of a later stage of chronic manganese poisoning. The drug is prepared from following raw herbal materials: herbs of indian abutilon, tall gastrodia tuber, Acorus gramineus Soland, altai anemone roots, chrysanthemum, oxygraphis glacialism, Chinese honey locust, bayberry roots, aquilariaceae malaccensis, bulbiferous stonescrop, tung tree roots, canscora, stem and leaves of cryptotaenia japonica hassk, puncturevine caltrop fruits, Saffron, Cyperus cyperoides, jasmine flowers, scabrousstem greenbrier rhizomes melitodes squamata nutting, asplenium incisum Thunb, murraya jasminorage, roots or stem of evergreen mucuna, aconiteleaf syneilesis herbs, fiddle-leaf fig roots and Japanese saussurea. The drug has the benefits as follows: the drug can be applied to treatment of the later stage of chronic manganese poisoning, Parkinson's syndrome, four-limb hypermyotonia, static tremor, lalopathy, gait difficulty and the like as well as mental symptoms including involuntary crying and laughing, obsessive thoughts, impulsive behaviors and the like can be relieved very well through drug therapy, the symptoms are eliminated through body regulation, so that the symptoms after poisoning are relieved very well, and the condition of a patient is greatly improved.
Owner:济南思拓新源医药科技有限公司
Traditional Chinese medicine composition for treating Parkinson's syndrome
InactiveCN104800606ANo side effectsHealth effectsNervous disorderPlant ingredientsCurative effectPARKINSON'S SYNDROME
The invention provides a traditional Chinese medicine composition for treating Parkinson's syndrome. The traditional Chinese medicine composition is prepared from the following raw materials by weight: 10-40 grams of oyster, 10-40 grams of figwort, 10-30 grams of thunberg fritillary bulbs, 10-30 grams of fried eucommia ulmoides, 10-30 grams of gastrodia tubers, 10-40 grams of semen cuscutae, 10-30 grams of common macrocarpium fruit, 10-30 grams of rhizoma alismatis, 10-30 grams of glutinous rehmannia, 10-40 grams of Chinese yam, 10-30 grams of cortex moutan, 10-40 grams of desertliving cistanche, 10-50 grams of rhizoma acori graminei, 10-40 grams of uncaria, 10-30 grams of peony and 10-40 grams of dendrobium. The traditional Chinese medicine composition for treating the Parkinson's syndrome is applied to the treatment based on differentiation of symptoms and signs in accordance with the Parkinson's syndrome, and has obvious curative effects.
Owner:赵汝君 +1
Parkinson's syndrome curative effect management method and device
PendingCN108735306ADetermining Response StatusAvoid inaccuraciesMedical communicationMedical automated diagnosisApproaches of managementCurative effect
The invention discloses a parkinson 's syndrome curative effect management method. The curative effect management method comprises the following steps of acquiring the medicine-taking information of apatient, wherein the medicine-taking information comprises the medicine-taking time and the medicine-taking dosage of the patient; acquiring the curative effect evaluation information of the patient;determining the treatment state of the patient on the basis of the medicine-taking information and the curative effect evaluation information; judging whether the treatment state meets a preset treatment condition or not, and generating a management scheme corresponding to the treatment state if the treatment state does not meet the preset treatment condition. The invention further discloses a parkinsonism syndrome curative effect management device. Accurate curative effect information of a patient is acquired in time, and the curative effect state of the patient is determined, so that the curative effect management scheme for the patient can be timely generated according to the curative effect of the patient in the treatment process, the rationality of curative effect management for treatment of a patient and the effectiveness of the treatment of the patient are improved, and the curative effect on the treatment of the patient is improved.
Owner:北京守帕健康科技有限公司
Medicine for treating Parkinson's disease
InactiveCN1634558AImprove microcirculation disorderDetermining DA agonismNervous disorderBacteriaMicroorganismPARKINSON'S SYNDROME
The invention relates to a therapeutic medicine for Parkinson's syndrome, characterized in that: No.33 bacterial of alpha streptococcus hemolyticus is carried to outer space by go and back type deep space vehicle and heredity mutation thereof occurs under the special condition of outer space. After returning to earth, bacterial with positive mutation and stable heredity are optimized and be cultured and bio-fermented to prepare medicine for Parkinson's syndrome. Said bacterial has been preserved by China General Microbiological Culture Collection Center with serial number of CGMCCNo. 1082. Said medicine for the treatment of Parkinson's disease is oral liquid containing mannon peptide 0.8g to15.0g produced by outer space mutated serial in 1000 ml thereof.
Owner:西安亨通光华制药有限公司
Novel compound and medical use thereof
InactiveUS20130245074A1Effective concentration of levodopaImprove Medication AdherenceBiocideNervous disorderSide effectBlood concentration
Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and / or therapeutic agent for Parkinson's disease and / or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.
Owner:ONO PHARMA CO LTD
Mirnas as biomarkers for parkinson's syndrome
Owner:HUMMINGBIRD DIAGNOSTICS GMBH
Intranasal delivery of levodopa power by precision olfactory device
Methods are provided for treating OFF episodes in a patient with Parkinson's disease or a Parkinson syndrome, comprising administering to a subject with Parkinson's disease or a Parkinson syndrome experiencing an OFF episode an effective dose of a dry pharmaceutical composition comprising L-DOPA, wherein the dose is administered by an intranasal delivery device that provides, following intranasaladministration, (a) a mean peak plasma levodopa concentration (Cmax) of at least 200 ng / mL, with (b) a mean time to Cmax (Tmax) of levodopa of less than or equal to 60 minutes. Dry pharmaceutical compositions of levodopa suitable for intranasal administration and unit dosage forms comprising the dry pharmaceutical compositions are also provided.
Owner:IMPEL NEUROPHARMA INC
Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient
Owner:ONO PHARMA CO LTD
Use of human growth hormone in multiple system atrophy
The invention relates to the use of a substance, which binds to and initiates signaling of the human growth hormone (hGH) receptor or a substance, which stimulates release or potentiates the activity of endogenous hGH, for treatment and / or prevention of Parkinsonism-Plus Syndromes. In particular, the invention relates to the use of hGH for the treatment and / or prevention of Multiple System Atrophy.
Owner:ARES TRADING SA
Processing method of flexible vibration sensor for monitoring Parkinson syndrome
ActiveCN111150368AReduce power consumptionImprove stabilityDiagnostic recording/measuringSensorsMedicineEngineering
The invention discloses a processing method of a flexible vibration sensor for monitoring Parkinson syndrome. The processing method includes the following steps of spin-coating photoresist, exposure,development, evaporation Ni film, removing glue and cleaning, growing CA self-crosslinking array, transferring to flexible substrate, clean and stripping, and sensor production. The flexible vibrationsensor produced by the processing method has the advantages of low power consumption, high stability and high sensitivity, so that the flexible vibration sensor has huge application potential in wearable health monitoring and has great potential in the direction of manufacturing low-cost and durable flexible sensors.
Owner:NORTHWESTERN POLYTECHNICAL UNIV
A kind of pharmaceutical composition for treating Parkinson's syndrome and its preparation method and application
ActiveCN107789504BPrecision medicineLow costNervous disorderUnknown materialsSide effectPharmaceutical drug
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE
Plant extract of the genus Zanthoxylum and its preparation method and use
Owner:CHENGDU DIAO JIU HONG PHARMACEUTICAL FACTORY
Method of independent or adjuvant treatment of Parkinson's disease and Parkinson's syndrome
Owner:LEE CHEN YU
A structure for writing in Parkinson's patients
Owner:绵阳鼎飞益电子科技有限公司
Compound and medical use thereof
InactiveUS8703816B2EffectiveImprove Medication AdherenceBiocideOrganic chemistryPropanoic acidSide effect
Owner:ONO PHARMA CO LTD
French marigold herb electuary having various health care effects
The invention discloses a French marigold herb. The French marigold herb is applied to medicinal electuary; and the French marigold herb has the efficacy of resisting to inflammation and reducing internal heat, and has improvement and prevention effects on prostatitis, gastrointestinal ulcer, Parkinson's syndrome, epilepsy, depression, climacteric syndrome, rhinitis, common cold due to wind-heat,pertussis, dysentery, costal gland diseases, mammary welling-abscess, furuncle, toothache, stomatitis, swelling and pain of eyes and adolescent acne. Steps of making the electuary by adopting the whole French marigold herb mainly include as follows: taking the whole French marigold herb to clean; performing air-drying and crushing into powder; and compacting the powder into small granules, and performing packaging and sealing. As the French marigold herb can be applied to the electuary, various functions of the French marigold herb can be integrated, so that people can obtain various efficacyof the French marigold herb by taking the electuary, and therefore, health care purposes can be achieved.
Owner:蔡德成
Single tablet dispensing box device suitable for Parkinson's syndrome
ActiveCN113071816AAchieve separationEasy to operateSmall article dispensingPharmaceutical containersPharmacy medicineDrug release
The invention discloses a single tablet dispensing box device suitable for Parkinson's syndrome. The device comprises a shell, a left cavity and a right cavity positioned on the left side and the right side of the shell, a medicine dispensing mechanism positioned in the left cavity, and a medicine storage cavity positioned in the right cavity. Compared with the prior art, the device is simple and reasonable in structure, single-time separation and medicine dispensing operation of tablets can be achieved through the medicine dispensing mechanism, when the medicine dispensing device is used, a patient can hold the device by hand and press a pressing rod with the thumb through a notch of the left cavity, the pressing rod drives a rotating rod to rotate and then drives an extrusion rod below to rotate, medicine in a medicine discharging cavity is released, and the medicine is taken out from a medicine outlet after the hand is released, and meanwhile, the pressing rod can drive an empty shell to move downwards, then a discharging mechanism on the lower portion can press the medicine in an inclined channel downwards to drive the medicine to the left side, the medicine enters the medicine discharging cavity, and use is more reasonable and convenient.
Owner:刘秀松
Selectivity M4 acceptor antagonist and medical use thereof
ActiveCN101209994BOrganic active ingredientsNervous disorderPharmaceutical drugBULK ACTIVE INGREDIENT
The invention provides a selective M4 receptor antagonist--levorotation demethylation phencynonate, non-toxic medicine salt thereof, medical composition that contains the levorotation demethylation phencynonate and non-toxic salt as active ingredients and application thereof in preparation of therapeutic drugs for motility dysfunctions of fremitus, rigor, etc. caused by Parkinson's syndrome (PD).The structure of the composition is showed in formula IIa.
Owner:BEIJING ZHONGYUANHENGKANG BIOTECHNOLOGY CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com